Retrospective analysis to validate the CTS5 in patients from El Alamo IV registry and GEICAM adjuvant studies.

ABSTRACT:

Background

Identifying high-risk of late recurrence (beyond 10 years) in patients with hormone receptor-positive HER2-negative early breast cancer (EBC) is crucial. The Clinical Treatment Score post-5 years (CTS5) score assesses recurrence risk after 5 years of endocrine therapy (ET). This study validated CTS5 as a prognostic tool for late recurrence by examining its association with Distant Recurrence-Free Survival using GEICAM study data and evaluating model calibration.

Patients and methods

We retrospectively analyzed 5739 hormone receptor-positive HER2-negative EBC patients from the El Álamo IV registry (N = 3509, diagnosed between 2002 and 2005) and 4 adjuvant GEICAM studies (N = 2680, conducted between 1996 and 2006). All patients were distant recurrence-free and alive

SUBMITTER: Lopez-Tarruella S 

PROVIDER: S-EPMC11969674 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature